A Turgut İlaçları study published in the Turkish Journal of Pharmaceutical Sciences indicated that Turgut’s TUR01, biosimilar to Amgen’s Humira® (adalimumab), was stable when stored under long-term storage conditions at for at least 18 months and for 24 months. In 2020, Turgut completed a phase I study to compare the pharmacokinetics, safety, tolerability, and immunogenicity of two formulations of adalimumab (TUR01 and EU Sourced Humira®). The results have not been disclosed.
Despite eight adalimumab biosimilar products available in the US, on 3 August 2023 Teva confirmed its intention to launch its AVT02 adalimumab biosimilar in 2024.